<DOC>
	<DOCNO>NCT00894101</DOCNO>
	<brief_summary>The purpose study investigate clinical value serial quantitative [ F-18 ] FLT PET image tool head neck cancer patient clinically schedule radiation radiation-chemotherapy combination term safety efficacy . Standard [ F-18 ] FDG PET active comparator .</brief_summary>
	<brief_title>Positron Emission Tomography Imaging With F-18 FLT Compared F-18 FDG Cancer Patients Treatment Evaluation</brief_title>
	<detailed_description />
	<mesh_term>Head Neck Neoplasms</mesh_term>
	<criteria>1 . Patient provide write Informed Consent willing comply protocol requirement 2 . Patient least 18 year age day dose ( male female race ethnicity ) 3 . Patient capable lying still PET scanner protocol require time frame ( ) 4 . Patient diagnosis one follow malignancy ( TNM Staging System ) : Lung cancer ( T3 grade , node positive , metastatic disease ) Head neck cancer ( T3 grade , node positive , metastatic disease ) 5 . Patient undergone comparative , diagnostic procedure lesion ( ) visible , ultrasound , include , limited compute tomography ( CT ) , magnetic resonance imaging ( MRI ) , nuclear medicine imaging , endoscopy , laparoscopy , standard abdominal xray , biopsy and/or surgery one mention area 6 . Patient schedule start radiotherapy chemoradiotherapy regimen curative intent 7 . As part his/her standard radiotherapy chemoradiotherapy regimen , patient schedule clinical [ F18 ] FDG PET scan pre treatment post treatment ( 4 week ( ±1 week ) start therapy ) 8 . Patient schedule investigational , pre treatment [ F18 ] FLT PET scan recommend within ± 2 day clinical , pre treatment [ F18 ] FDG PET scan 9 . Patient receive intend receive 5fluorouracil ( 5FUchemotherapeutic agent ) 10 . Patient score great equal ( ≥ ) 60 % Karnofsky Performance Status Scale Exclude patient study patient fulfill inclusion criterion , follow condition observe : 1 . Patient pregnant lactate female . These method use exclude possibility pregnancy : test site institution ( serum urine βHCG ) within 48 hour prior start investigational product administration , surgical history ( eg , tubal ligation hysterectomy ) , patient 's history post menopausal minimum 1 year without menses . 2 . Patient undergoing treatment palliative intent 3 . Patient receive investigational compound and/or medical device within 14 day admission study 4 . Patient medical condition circumstance would significantly decrease chance obtain reliable data , achieve study objective , complete study and/or postdose followup examination 5 . Patient determine Investigator he/she clinically unsuitable study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2011</verification_date>
</DOC>